{"_buckets": {"deposit": "21a022e8-0aa3-4514-85fc-8896d48028e1"}, "_deposit": {"id": "3962", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3962"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003962", "sets": ["461:462"]}, "author_link": ["8274", "8275", "8276", "8277", "8278", "8279", "8280", "8281", "8282", "8283"], "item_1628147817048": {"attribute_name": "\u51fa\u7248\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2008", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "17", "bibliographicPageEnd": "1522", "bibliographicPageStart": "1517", "bibliographicVolumeNumber": "47", "bibliographic_titles": [{"bibliographic_title": "INTERNAL MEDICINE"}]}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_31": {"attribute_name": "\u30d5\u30a9\u30fc\u30de\u30c3\u30c8\uff1amime\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "INTERNAL MEDICINE. 47(17):1517-1522(2008)", "subitem_description_type": "Other"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000259221300004"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "JAPAN SOC INTERNAL MEDICINE"}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.2169/internalmedicine.47.0949"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.2169/internalmedicine.47.0949", "subitem_relation_type_select": "DOI"}}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0918-2918", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0918-2918", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10827774", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "primary systemic AL amyloidosis; cyclic VAD (vincristine, doxorubicin and dexamethasone); plasma cell dyscrasia; nephrotic syndrome"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; LIGHT-CHAIN AMYLOIDOSIS; NEPHROTIC SYNDROME; MULTIPLE-MYELOMA; SUPPORT; CHEMOTHERAPY; CRITERIA"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Objective Intensive chemotherapy targeting plasma cell dyscrasia has been recently employed for the treatment of primary systemic AL amyloidosis. We prospectively studied the clinical usefulness of cyclic VAD (vincristine, doxorubicin and dexamethasone) in patients with primary systemic AL amyloidosis who were ineligible for high-dose melphalan with autologous stem cell support. Patients and Methods Eight patients (mean age, 60.4+/-8.8 years) were treated with cyclic VAD until the disappearance of M-protein from both serum and urine. Of these, seven showed nephrotic syndrome before the start of VAD irrespective of a decrease in creatinine clearance. Serial follow-up studies after VAD evaluated hematological status and organ function. Results Four patients (50%) showed a marked decrease in abnormal plasma cells in the bone marrow and normalized kappa/lambda ratios of serum free light chain in conjunction with disappearance of M-protein after 1 to 3 courses of VAD. There were no serious adverse events, and nephrotic syndrome gradually improved with no hematological relapse in the follow-up period of 3 to 5 years. The remaining 4 patients showed worsening of congestive heart failure and/or systemic edema ascribable to dexamethasone, resulting in cessation of cyclic VAD before disappearance of M-protein. All of these patients died of multiple organ failure or required permanent hemodialysis within 1 year after the start of cyclic VAD. Conclusion Cyclic VAD is a potent therapeutic option in primary systemic AL amyloidosis, but in patients with renal or cardiac dysfunction careful management for adverse events, especially body fluid retention, is necessary."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Tazawa,  K", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8274", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuda,  M", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8275", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida,  T"}], "nameIdentifiers": [{"nameIdentifier": "8276", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Gono,  T", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8277", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katoh,  N", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8278", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimojima,  Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8279", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishii,  W", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8280", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fushimi,  T", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8281", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koyama,  J", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8282", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda,  SI", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "8283", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "VAD-IM.pdf", "filesize": [{"value": "207.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 207900.0, "url": {"label": "VAD-IM.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3962/files/VAD-IM.pdf"}, "version_id": "5c34843e-8752-46d3-8c97-90d4241f0b9f"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/1386", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2008-10-30"}, "publish_date": "2008-10-30", "publish_status": "0", "recid": "3962", "relation": {}, "relation_version_is_last": true, "title": ["Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients"], "weko_shared_id": -1}